Neumann S, Jung W, Trümper L
Abteilung Hämatologie und Onkologie, Zentrum Innere Medizin, Universitätsmedizin Göttingen, 37099, Göttingen, Deutschland.
Internist (Berl). 2007 Apr;48(4):362-71. doi: 10.1007/s00108-007-1824-y.
Non-Hodgkin's lymphomas represent a clinically and biologically heterogeneous group of diseases. Over the last few years, new treatment approaches such as humoral immunotherapy and high dose therapy with stem cell rescue have improved the chances for a cure in most patients with malignant lymphoma. However, only with the correct diagnosis and staging, including the evaluation of novel prognostic factors, are treating physicians able to choose the optimal treatment for their patients. This review focuses on conventional staging procedures and their role in the management of lymphoma patients, as well as on some new aspects of the molecular classification of lymphomas.
非霍奇金淋巴瘤是一组临床和生物学上异质性的疾病。在过去几年中，诸如体液免疫疗法和干细胞救援高剂量疗法等新的治疗方法提高了大多数恶性淋巴瘤患者的治愈几率。然而，只有通过正确的诊断和分期，包括评估新的预后因素，治疗医生才能为患者选择最佳治疗方案。本综述重点关注传统分期程序及其在淋巴瘤患者管理中的作用，以及淋巴瘤分子分类的一些新方面。
